PT -期刊文章盟Edoardo卢卡雷利AU -弗朗西斯科·Falbo盟西尔维亚Basaia AU -卡米拉Cividini盟尼洛莉娃AU - Elisa Canu盟Veronica Castelnovo AU -朱塞佩·马格纳尼盟弗朗西斯卡卡索盟Paola Caroppo AU -萨拉Prioni盟Giacomina罗西AU -卢西奥Tremolizzo盟Ildebrando Appollonio盟Vincenzo Silani AU -马西莫菲利皮主持盟Federica Agosta TI -功能连通性重组地震震中在额颞叶大叶性传播疾病变性变体(p12 - 3.001) DP - 2022年5月03 TA -神经病学第六PG - 1332 - 98 IP - 18补充4099 - //www.ez-admanager.com/content/98/18_Supplement/1332.short 4100 - //www.ez-admanager.com/content/98/18_Supplement/1332.full所以Neurology2022可能03;首页98 AB -目的:探索逐步功能连通性(证监会)重组影响患者额颞叶大叶性变性(FTLD)变异。背景:虽然FTLD临床表现分享额叶和颞叶的伤害,有一个明显的分歧在大脑网络的脆弱性,导致异构症状伴随行为变异的额颞叶痴呆(bvFTD)和迟滞型(nfvPPA)和语义变体原发性进行性失语(svPPA)。证监会分析是一个graph-theory-based神经影像学方法,检测整个大脑功能耦合的选择感兴趣的区域,增加link-step距离。设计/方法:患者bvFTD (n = 26), nfvPPA (n = 11)或svPPA (n = 14)进行了临床评估和3 t MRI扫描。对于每个子群,皮质厚度进行评估,以确定萎缩的峰值(视为疾病中心),与37岁相比,sex-matched健康对照组。这些区域被用作随后证监会种子区域分析。结果:选择种子区域bvFTD右眶额皮质,nfvPPA左辅助运动区,左颞极svPPA。与控制相比,病人三个组表现为广泛的地区,香港证监会降低直接与各自的种子/中间连接的地区。bvFTD nfvPPA病人也显示增加香港证监会在大脑区域靠近各自的种子区域和同源侧皮质link-step。进一步link-steps,证监会增加也观察到后小脑bvFTD nfvPPA病人,和优越的额叶皮层svPPA病人。Conclusions: Our findings indicate an increase in the short-range direct connectivity around the disease epicenters of FTLD, probably as a compensation for neurodegeneration, in contrast with widespread functional rearrangements that characterize each phenotype across different link-steps. This was the first study exploring SFC in FTLD, opening promising perspectives to understand the physiopathological underpinnings of these presentations and model disease evolution.Disclosure: Dr. Spinelli has nothing to disclose. Dr. Falbo has nothing to disclose. Silvia Basaia has nothing to disclose. Camilla Cividini has nothing to disclose. Nilo Riva has nothing to disclose. The institution of Elisa Canu has received research support from Italian Ministry of Health . Veronica Castelnovo has nothing to disclose. Giuseppe Magnani has nothing to disclose. Dr. Caso has nothing to disclose. Paola Caroppo has nothing to disclose. Sara Prioni has nothing to disclose. Dr. Rossi has nothing to disclose. Lucio Tremolizzo has nothing to disclose. Dr. Appollonio has nothing to disclose. Dr. Silani has nothing to disclose. Dr. Filippi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Bayer, Biogen Idec, Merck-Serono, Novartis, Roche, Sanofi Genzyme, Takeda, and Teva Pharmaceutical Industries. Dr. Filippi has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Bayer, Biogen Idec, Merck-Serono, Novartis, Roche, Sanofi Genzyme, Takeda, and Teva Pharmaceutical Industries. Dr. Filippi has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Springer Nature. The institution of Dr. Filippi has received research support from Biogen Idec, Merck-Serono, Novartis, Roche, Teva Pharmaceutical Industries, Italian Ministry of Health, Fondazione Italiana Sclerosi Multipla, and ARiSLA (Fondazione Italiana di Ricerca per la SLA). Federica Agosta has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Philips. Federica Agosta has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier INC.